Markets:

Overview

News

Currencies

International

Treasuries

Outlook Therapeutics, Inc. - Common Stock (NQ:OTLK)

0.2260 +0.0060 (+2.73%)

Streaming Delayed Price Updated: 1:44 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Outlook Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Wondering what's happening in today's pre-market session? ↗

August 28, 2025

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 28, 2025

Via Benzinga

Outlook Therapeutics Stock Nose-Dives 66% In Pre-Market – Here’s Why ↗

August 28, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 27, 2025

Via Benzinga

Top 3 Health Care Stocks That Could Blast Off This Month ↗

January 06, 2025

Via Benzinga

Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket ↗

August 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 26, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 18, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Outlook Therapeutics Reports Q3 Revenue ↗

August 14, 2025

Via The Motley Fool

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

July 22, 2025

Via ACCESS Newswire

Rubrik To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday ↗

June 06, 2025

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

May 23, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

June 04, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:OTLK),(NASDAQ:EYEN),(NYSE:BLCO),(NASDAQ:BMEA) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 22, 2025

Via Benzinga

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

June 04, 2025

From FN Media Group LLC

Via GlobeNewswire

Thursday's after hours session: top gainers and losers ↗

May 22, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug ↗

January 16, 2025

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

Via Benzinga

This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

December 02, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 27, 2024

Via Benzinga

Nasdaq Down Over 100 Points; HP Shares Plunge ↗

November 27, 2024

Via Benzinga

Dow Falls Over 100 Points; US Crude Oil Stocks Decline ↗

November 27, 2024

Via Benzinga

Topics Stocks

US Stocks Mixed; Economy Grows By 2.8% In Q3 ↗

November 27, 2024

Via Benzinga

Topics Economy

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? ↗

November 27, 2024

Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile.

Via Benzinga

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 11, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 03, 2024

Via Benzinga

OTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024 ↗

August 14, 2024

OTLK stock results show that Outlook Therapeutics beat analyst estimates for earnings per share the third quarter of 2024.

Via InvestorPlace

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

July 11, 2024

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Via MarketBeat

3 Undervalued Gems Set to Soar 1,000% by 2026 ↗

June 25, 2024

Discover the fundamentals behind three undervalued stocks to buy in the oil and gas, advertising, and biotechnology industries.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.